在晚期头颈癌的二线治疗中测试研究药物 Atezolizumab 和/或 Bevacizumab 联合或不联合标准化疗的使用
化疗 + 西妥昔单抗 vs 化疗 + 贝伐珠单抗 vs Atezolizumab + 贝伐珠单抗在复发/转移性头颈癌免疫检查点抑制进展后的 II/III 期试验
This phase II/III compares the standard therapy (chemotherapy plus cetuximab) versus adding bevacizumab to standard chemotherapy, versus combination of just bevacizumab and atezolizumab in treating patients with head and neck cancer that has spread to other places in the body (metastatic or advanced stage) or has come back after prior treatment (recurrent). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Cisplatin and carboplatin are in a class of chemotherapy medications known as platinum-containing compounds. They work by killing, stopping, or slowing the growth of cancer cells. Docetaxel is in a class of chemotherapy medications called taxanes. It stops cancer cells from growing and dividing and may kill them. The addition of bevacizumab to standard chemotherapy or combination therapy with bevacizumab and atezolizumab may be better than standard chemotherapy plus cetuximab in treating patients with recurrent/metastatic head and neck cancers.
研究概览
地位
条件
- 复发性头颈部鳞状细胞癌
- 复发性下咽鳞状细胞癌
- 复发性喉鳞状细胞癌
- 转移性头颈部鳞状细胞癌
- 临床 IV 期 HPV 介导的(p16 阳性)口咽癌 AJCC v8
- IV 期下咽癌 AJCC v8
- IV 期喉癌 AJCC v8
- IV 期唇部和口腔癌 AJCC v8
- IV 期口咽(p16 阴性)癌 AJCC v8
- 转移性下咽鳞状细胞癌
- 转移性喉鳞状细胞癌
- 转移性唇和口腔癌
- 转移性鼻腔鳞状细胞癌
- 转移性鼻咽鳞状细胞癌
- 转移性咽鳞状细胞癌
- 转移性鼻窦鳞状细胞癌
- 复发性唇和口腔鳞状细胞癌
- 复发性鼻咽鳞状细胞癌
- 复发性咽鳞状细胞癌
- 复发性鼻窦鳞状细胞癌
- IV 期鼻咽癌 AJCC v8
- IV 期鼻窦癌 AJCC v8
- 第四阶段头和颈皮肤鳞状细胞癌AJCC V8
详细说明
PRIMARY OBJECTIVES:
I. To evaluate progression-free survival (PFS) of patients treated with chemotherapy plus cetuximab, chemotherapy plus bevacizumab, and atezolizumab plus bevacizumab. (Phase II) II. To evaluate the overall survival (OS) of patients treated with chemotherapy plus cetuximab to the superior arm from the phase II portion of the protocol. (Phase III)
SECONDARY OBJECTIVES:
I. To evaluate the OS for the subset of patients with high PD-L1 expression, defined as combined positive score (CPS) >= 20% on all arms of treatment.
II. To evaluate the toxicity of each arm of treatment.
IMAGING OBJECTIVES:
I. To establish the correlation between fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET) and computed tomography (CT) neck imaging biomarkers (maximum standard uptake value [SUVmax], metabolic tumor volume [MTV], total lesion glycolysis [TLG], tumor volume) and expression of PD-L1 expression (Low versus high, defined as CPS < 20 versus CPS >= 20).
II. To determine if 18FDG-PET/CT and CT neck imaging biomarkers at baseline will predict treatment response at nine to twelve weeks post the initiation of treatment, PFS, and OS.
EXPLORATORY OBJECTIVE:
I. To establish the correlation between 18F-FDG PET and CT neck radiomics features and PD-L1 expressions (Low versus high - defined as CPS < 20 versus CPS >= 20).
OUTLINE: This is a randomized phase II trial followed by a randomized phase III trial.
PHASE II: Patients are randomized to 1 of 3 arms.
ARM A: Patients receive cetuximab intravenously (IV) over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or magnetic resonance imaging (MRI) throughout the trial. Patients may undergo echocardiography (ECHO) during screening.
ARM B: Patients receive bevacizumab IV over 30-90 minutes on day 1 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-60 minutes on day 1 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening.
ARM C: Patients receive bevacizumab IV over 30-90 minutes on day 1 and atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening.
PHASE III: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening.
ARM B: Patients receive treatment as in Arm B or C above based on results of the Phase II trial.
Patients undergo blood sample collection throughout the study.
After completion of study treatment, patients are followed up at 30 days and then every 3 months if patient is < 2 years from randomization and every 6 months if patient is 2-5 years from randomization.
研究类型
注册 (估计的)
阶段
- 阶段2
- 第三阶段
联系人和位置
学习地点
-
-
Arkansas
-
Little Rock、Arkansas、美国、72205
- University of Arkansas for Medical Sciences
-
-
California
-
Dublin、California、美国、94568
- Epic Care-Dublin
-
Emeryville、California、美国、94608
- Epic Care Partners in Cancer Care
-
Irvine、California、美国、92612
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Martinez、California、美国、94553-3156
- Contra Costa Regional Medical Center
-
Orange、California、美国、92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Palo Alto、California、美国、94304
- VA Palo Alto Health Care System
-
Palo Alto、California、美国、94304
- Stanford Cancer Institute Palo Alto
-
-
Connecticut
-
Derby、Connecticut、美国、06418
- Smilow Cancer Hospital-Derby Care Center
-
Fairfield、Connecticut、美国、06824
- Smilow Cancer Hospital Care Center-Fairfield
-
Glastonbury、Connecticut、美国、06033
- Smilow Cancer Hospital Care Center at Glastonbury
-
Greenwich、Connecticut、美国、06830
- Smilow Cancer Hospital Care Center at Greenwich
-
Guilford、Connecticut、美国、06437
- Smilow Cancer Hospital Care Center - Guilford
-
Hartford、Connecticut、美国、06105
- Smilow Cancer Hospital Care Center at Saint Francis
-
New Haven、Connecticut、美国、06520
- Yale University
-
North Haven、Connecticut、美国、06473
- Yale-New Haven Hospital North Haven Medical Center
-
Orange、Connecticut、美国、06477
- Smilow Cancer Hospital-Orange Care Center
-
Stamford、Connecticut、美国、06902
- Smilow Cancer Hospital Care Center at Long Ridge
-
Torrington、Connecticut、美国、06790
- Smilow Cancer Hospital-Torrington Care Center
-
Trumbull、Connecticut、美国、06611
- Smilow Cancer Hospital Care Center-Trumbull
-
Waterbury、Connecticut、美国、06708
- Smilow Cancer Hospital-Waterbury Care Center
-
Waterford、Connecticut、美国、06385
- Smilow Cancer Hospital Care Center - Waterford
-
-
Delaware
-
Newark、Delaware、美国、19713
- Helen F Graham Cancer Center
-
Newark、Delaware、美国、19713
- Medical Oncology Hematology Consultants PA
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20010
- MedStar Washington Hospital Center
-
-
Florida
-
Coral Gables、Florida、美国、33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach、Florida、美国、33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Fort Lauderdale、Florida、美国、33316
- Broward Health Medical Center
-
Miami、Florida、美国、33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami、Florida、美国、33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation、Florida、美国、33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Georgia
-
Atlanta、Georgia、美国、30308
- Emory University Hospital Midtown
-
Atlanta、Georgia、美国、30322
- Emory University Hospital/Winship Cancer Institute
-
-
Hawaii
-
Honolulu、Hawaii、美国、96813
- Queen's Medical Center
-
Honolulu、Hawaii、美国、96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu、Hawaii、美国、96813
- Queen's Cancer Cenrer - POB I
-
Honolulu、Hawaii、美国、96817
- Queen's Cancer Center - Kuakini
-
‘Aiea、Hawaii、美国、96701
- Hawaii Cancer Care - Westridge
-
-
Idaho
-
Boise、Idaho、美国、83712
- Saint Luke's Cancer Institute - Boise
-
Coeur d'Alene、Idaho、美国、83814
- Kootenai Health - Coeur d'Alene
-
Fruitland、Idaho、美国、83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian、Idaho、美国、83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa、Idaho、美国、83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls、Idaho、美国、83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint、Idaho、美国、83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls、Idaho、美国、83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Aurora、Illinois、美国、60504
- Rush-Copley Medical Center
-
Centralia、Illinois、美国、62801
- Centralia Oncology Clinic
-
Chicago、Illinois、美国、60637
- University of Chicago Comprehensive Cancer Center
-
Chicago、Illinois、美国、60612
- University of Illinois
-
Chicago、Illinois、美国、60612
- John H Stroger Jr Hospital of Cook County
-
Danville、Illinois、美国、61832
- Carle at The Riverfront
-
Decatur、Illinois、美国、62526
- Decatur Memorial Hospital
-
Decatur、Illinois、美国、62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham、Illinois、美国、62401
- Crossroads Cancer Center
-
Effingham、Illinois、美国、62401
- Carle Physician Group-Effingham
-
Harvey、Illinois、美国、60426
- Ingalls Memorial Hospital
-
Mattoon、Illinois、美国、61938
- Carle Physician Group-Mattoon/Charleston
-
New Lenox、Illinois、美国、60451
- UC Comprehensive Cancer Center at Silver Cross
-
O'Fallon、Illinois、美国、62269
- Cancer Care Center of O'Fallon
-
O'Fallon、Illinois、美国、62269
- HSHS Saint Elizabeth's Hospital
-
Orland Park、Illinois、美国、60462
- University of Chicago Medicine-Orland Park
-
Springfield、Illinois、美国、62702
- Southern Illinois University School of Medicine
-
Springfield、Illinois、美国、62702
- Springfield Clinic
-
Springfield、Illinois、美国、62781
- Springfield Memorial Hospital
-
Urbana、Illinois、美国、61801
- Carle Cancer Center
-
Yorkville、Illinois、美国、60560
- Rush-Copley Healthcare Center
-
-
Iowa
-
Ames、Iowa、美国、50010
- Mary Greeley Medical Center
-
Ames、Iowa、美国、50010
- McFarland Clinic - Ames
-
Ankeny、Iowa、美国、50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Boone、Iowa、美国、50036
- McFarland Clinic - Boone
-
Clive、Iowa、美国、50325
- Mercy Cancer Center-West Lakes
-
Clive、Iowa、美国、50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Creston、Iowa、美国、50801
- Greater Regional Medical Center
-
Des Moines、Iowa、美国、50309
- Iowa Methodist Medical Center
-
Des Moines、Iowa、美国、50314
- Mercy Medical Center - Des Moines
-
Des Moines、Iowa、美国、50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines、Iowa、美国、50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Fort Dodge、Iowa、美国、50501
- McFarland Clinic - Trinity Cancer Center
-
Jefferson、Iowa、美国、50129
- McFarland Clinic - Jefferson
-
Marshalltown、Iowa、美国、50158
- McFarland Clinic - Marshalltown
-
Waukee、Iowa、美国、50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
West Des Moines、Iowa、美国、50266
- Mercy Medical Center-West Lakes
-
-
Louisiana
-
New Orleans、Louisiana、美国、70112
- University Medical Center New Orleans
-
-
Maryland
-
Baltimore、Maryland、美国、21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore、Maryland、美国、21204
- Greater Baltimore Medical Center
-
Baltimore、Maryland、美国、21201
- University of Maryland/Greenebaum Cancer Center
-
Cumberland、Maryland、美国、21502
- UPMC Western Maryland
-
-
Massachusetts
-
Worcester、Massachusetts、美国、01655
- UMass Memorial Medical Center - University Campus
-
-
Minnesota
-
Coon Rapids、Minnesota、美国、55433
- Mercy Hospital
-
Minneapolis、Minnesota、美国、55415
- Hennepin County Medical Center
-
Minneapolis、Minnesota、美国、55407
- Abbott-Northwestern Hospital
-
Saint Louis Park、Minnesota、美国、55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul、Minnesota、美国、55101
- Regions Hospital
-
-
Missouri
-
Cape Girardeau、Missouri、美国、63703
- Saint Francis Medical Center
-
St Louis、Missouri、美国、63128
- Mercy Hospital South
-
-
Montana
-
Anaconda、Montana、美国、59711
- Community Hospital of Anaconda
-
Billings、Montana、美国、59101
- Billings Clinic Cancer Center
-
Bozeman、Montana、美国、59715
- Bozeman Health Deaconess Hospital
-
Great Falls、Montana、美国、59405
- Benefis Sletten Cancer Institute
-
Missoula、Montana、美国、59804
- Community Medical Center
-
-
New Hampshire
-
Lebanon、New Hampshire、美国、03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Mexico
-
Albuquerque、New Mexico、美国、87106
- University of New Mexico Cancer Center
-
Las Cruces、New Mexico、美国、88011
- Memorial Medical Center-Las Cruces
-
-
North Carolina
-
Clinton、North Carolina、美国、28328
- Southeastern Medical Oncology Center-Clinton
-
Goldsboro、North Carolina、美国、27534
- Southeastern Medical Oncology Center-Goldsboro
-
Jacksonville、North Carolina、美国、28546
- Southeastern Medical Oncology Center-Jacksonville
-
-
Ohio
-
Centerville、Ohio、美国、45459
- Miami Valley Hospital South
-
Dayton、Ohio、美国、45409
- Miami Valley Hospital
-
Dayton、Ohio、美国、45415
- Miami Valley Hospital North
-
Dayton、Ohio、美国、45415
- Dayton Physician LLC - Englewood
-
Dayton、Ohio、美国、45409
- Premier Blood and Cancer Center
-
Franklin、Ohio、美国、45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Greenville、Ohio、美国、45331
- Miami Valley Cancer Care and Infusion
-
Kettering、Ohio、美国、45429
- Kettering Medical Center
-
Steubenville、Ohio、美国、43952
- Trinity's Tony Teramana Cancer Center
-
Toledo、Ohio、美国、43623
- Toledo Clinic Cancer Centers-Toledo
-
Troy、Ohio、美国、45373
- Upper Valley Medical Center
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Clackamas、Oregon、美国、97015
- Providence Cancer Institute Clackamas Clinic
-
Newberg、Oregon、美国、97132
- Providence Newberg Medical Center
-
Portland、Oregon、美国、97213
- Providence Portland Medical Center
-
Portland、Oregon、美国、97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Altoona、Pennsylvania、美国、16601
- UPMC Altoona
-
Beaver、Pennsylvania、美国、15009
- UPMC-Heritage Valley Health System Beaver
-
Butler、Pennsylvania、美国、16001
- UPMC Hillman Cancer Center at Butler Health System
-
Camp Hill、Pennsylvania、美国、17011
- UPMC Camp Hill
-
Carlisle、Pennsylvania、美国、17015
- Carlisle Regional Cancer Center
-
Cranberry Township、Pennsylvania、美国、16066
- UPMC Hillman Cancer Center - Passavant - Cranberry
-
Erie、Pennsylvania、美国、16505
- UPMC Hillman Cancer Center Erie
-
Farrell、Pennsylvania、美国、16121
- UPMC Cancer Center at UPMC Horizon
-
Greensburg、Pennsylvania、美国、15601
- UPMC Cancer Centers - Arnold Palmer Pavilion
-
Greenville、Pennsylvania、美国、16125
- UPMC Hillman Cancer Center in Greenville/UPMC Horizon
-
Harrisburg、Pennsylvania、美国、17109
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus
-
Indiana、Pennsylvania、美国、15701
- IRMC Cancer Center
-
Johnstown、Pennsylvania、美国、15901
- UPMC-Johnstown/John P. Murtha Regional Cancer Center
-
McKeesport、Pennsylvania、美国、15132
- UPMC Cancer Center at UPMC McKeesport
-
Mechanicsburg、Pennsylvania、美国、17050
- UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
-
Monroeville、Pennsylvania、美国、15146
- Forbes Hospital
-
Monroeville、Pennsylvania、美国、15146
- UPMC Hillman Cancer Center - Monroeville
-
Moon Township、Pennsylvania、美国、15108
- UPMC Hillman Cancer Center in Coraopolis
-
Mount Pleasant、Pennsylvania、美国、15666
- UPMC Hillman Cancer Center - Part of Frick Hospital
-
N. Huntingdon、Pennsylvania、美国、15642
- Arnold Palmer Cancer Center Medical Oncology Norwin
-
Natrona Heights、Pennsylvania、美国、15065
- UPMC Cancer Center-Natrona Heights
-
New Castle、Pennsylvania、美国、16105
- UPMC Hillman Cancer Center - New Castle
-
Philadelphia、Pennsylvania、美国、19107
- Thomas Jefferson University Hospital
-
Philadelphia、Pennsylvania、美国、19114
- Jefferson Torresdale Hospital
-
Pittsburgh、Pennsylvania、美国、15212
- Allegheny General Hospital
-
Pittsburgh、Pennsylvania、美国、15232
- UPMC Hillman Cancer Center
-
Pittsburgh、Pennsylvania、美国、15215
- UPMC-Saint Margaret
-
Pittsburgh、Pennsylvania、美国、15237
- UPMC-Passavant Hospital
-
Pittsburgh、Pennsylvania、美国、15243
- UPMC-Saint Clair Hospital Cancer Center
-
Pittsburgh、Pennsylvania、美国、15219
- UPMC-Mercy Hospital
-
Seneca、Pennsylvania、美国、16346
- UPMC Cancer Center at UPMC Northwest
-
Uniontown、Pennsylvania、美国、15401
- UPMC Cancer Center-Uniontown
-
Washington、Pennsylvania、美国、15301
- UPMC Cancer Center-Washington
-
West Mifflin、Pennsylvania、美国、15122
- UPMC West Mifflin-Cancer Center Jefferson
-
Williamsport、Pennsylvania、美国、17754
- Divine Providence Hospital
-
Willow Grove、Pennsylvania、美国、19090
- Asplundh Cancer Pavilion
-
York、Pennsylvania、美国、17408
- UPMC Memorial
-
-
Rhode Island
-
Westerly、Rhode Island、美国、02891
- Smilow Cancer Hospital Care Center - Westerly
-
-
South Dakota
-
Rapid City、South Dakota、美国、57701
- Rapid City Regional Hospital
-
-
Tennessee
-
Knoxville、Tennessee、美国、37916
- Covenant Health Cancer Centers
-
Knoxville、Tennessee、美国、37932
- Covenant Health Cancer Centers - West
-
Lenoir City、Tennessee、美国、37772
- Covenant Health Oncology Group - Lenoir City
-
Nashville、Tennessee、美国、37232
- Vanderbilt University/Ingram Cancer Center
-
Oak Ridge、Tennessee、美国、37830
- Covenant Health Oncology Group - Oak Ridge
-
-
Vermont
-
Saint Johnsbury、Vermont、美国、05819
- Dartmouth Cancer Center - North
-
-
West Virginia
-
Charleston、West Virginia、美国、25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
-
Wisconsin
-
Mukwonago、Wisconsin、美国、53149
- ProHealth D N Greenwald Center
-
Oconomowoc、Wisconsin、美国、53066
- ProHealth Oconomowoc Memorial Hospital
-
Waukesha、Wisconsin、美国、53188
- UW Cancer Center at ProHealth Care
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Patient must have histologically confirmed squamous cell carcinoma of the head and neck (HNSCC) (excluding squamous cell carcinoma [SCC] of salivary glands, Epstein-Barr virus [EBV]-associated nasopharynx and skin)
-
Patient must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1. Measurements must be obtained within 4 weeks prior to randomization
-
Patient must be >= 18 years of age
-
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1
-
Patient must have disease progression after prior therapy with an immune checkpoint inhibitor (ICI) in the first-line setting for recurrent/metastatic disease. Patient must have received first-line immune checkpoint inhibition for at least 6 weeks. Patients who have recurred or progressed within 12 weeks of immune checkpoint inhibition administered in the definitive setting for locally advanced disease (for e.g., in the context of a clinical trial) will also be eligible if local therapies are not feasible
-
Prior combination immunotherapies are permitted, but patient must not have had prior antiangiogenic treatment (e.g., bevacizumab, ziv-aflibercept, ramucirumab, sorafenib, sunitinib, pazopanib, regorafenib, lenvatinib, etc.). Patient must have completed any prior investigational therapy at least 28 days prior to randomization.
- NOTE: Patients who received platinum/taxanes in the locally-advanced or recurrent/metastatic setting and did not progress for at least 4 months thereafter, will be eligible for this study. Patients who received cetuximab in the locally-advanced setting and did not progress for at least 4 months thereafter, will also be eligible for this study
-
Patient must not have a history of >= grade 3 immune-related adverse event on prior ICI therapy (except those that could be managed with steroids [e.g., dermatologic toxicity, asymptomatic elevation of pancreatic enzymes, etc.]) and ICI could eventually be resumed. Patients who developed grade 3 endocrinopathies but are now stable on hormone supplementation and/or a daily prednisone dose of =< 10 mg (or equivalent doses of another glucocorticoid), will be permitted on this trial
-
Patient must not have a history of PD-1 inhibitor-induced hyper-progression, defined as 100% increase in tumor burden within 8 weeks (or 50% within 4 weeks) of initiating ICI and associated with clinical deterioration
-
Patient must not have any of the following criteria due to the possibility of increased risk for tumor bleeding with bevacizumab therapy:
- Prior carotid bleeding,
- Tumors that invade major vessels (e.g., the carotid) as shown unequivocally by imaging studies,
- Central (e.g., within 2 cm from the hilum) lung metastases that are cavitary as shown unequivocally by imaging studies,
- Any prior history of bleeding related to the current head and neck cancer,
- History of gross hemoptysis (bright red blood of 1/2 teaspoon or more per episode of coughing) within 3 months prior to randomization
-
Patient must not have uncontrolled hypertension, a history of hypertensive crisis or hypertensive encephalopathy, or a history of grade 4 thromboembolism
-
Patient must not have a history of coagulopathy or hemorrhagic disorders
-
Patient must not have a history of thrombosis (e.g., pulmonary embolism or deep venous thrombosis) currently requiring therapeutic anticoagulation (prophylactic use of anticoagulation is allowed)
-
Patient must not be receiving chronic daily treatment with aspirin (> 325 mg/day) or non-steroidal anti-inflammatory agents (NSAID's) known to inhibit platelet function. The use of anti-platelet agents [e.g., dipyridamole (Persatine), ticlopidine (Ticlid), clopidogrel (Plavix)] is allowed only if patient is not receiving concurrent aspirin or NSAID's known to inhibit platelet function
-
Patient must have PD-L1 expression >= 1% by CPS in the tumor and/or immune cells
- NOTE: Enrolling centers should test for PD-L1 CPS preferably using the SP263 assay. Where this is not feasible, using their preferred Clinical Laboratory Improvement Act (CLIA)-certified or similar assay will be accepted. It is preferred for standard of care (SOC) PD-L1 assessments to be done on post-first line ICI samples if available, but SOC PD-L1 assessments on pre-ICI samples will be accepted for eligibility
-
Patient must not have a severe infection within 4 weeks prior to randomization, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia. Patients must not have active tuberculosis
-
Patient must not have a history of non-infectious pneumonitis requiring steroids at doses greater than or equal to 10 mg per day of prednisone or the equivalent on first line immunotherapy
-
Patient must not have a history of solid organ transplantation or stem-cell transplant
-
Patient must not be on immunosuppressive medication within 7 days prior to randomization except for: intranasal, inhaled, or topical steroids, local steroid injection, systemic corticosteroids at doses less than or equal to 10 mg per day of prednisone or the equivalent, or steroids used as premedication for hypersensitivity reactions
-
Patient must not have an active autoimmune disease that requires systemic treatment within 2 years prior to randomization. Patients who are receiving replacement therapy for adrenal or pituitary insufficiency will not be excluded
-
Patient must not have had a severe hypersensitivity reaction to any of the drug components used on this protocol or to chimeric or humanized antibodies or fusion proteins
-
Patient must not have received any live vaccine within 30 days prior to randomization and while participating in the study (and continue for 5 months after the last dose of atezolizumab on Arm C). Live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine. Patients are permitted to receive inactivated vaccines and any non-live vaccines including those for the seasonal influenza and coronavirus disease 2019 (COVID-19) (Note: intranasal influenza vaccines, such as Flu-Mist [registered trademark] are live attenuated vaccines and are not allowed). If possible, it is recommended to separate study drug administration from vaccine administration by about a week (primarily, in order to minimize an overlap of adverse events
-
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.
- All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy.
- A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for 2 months after the last dose of treatment for patients assigned to Arm A and for 6 months after the last dose of protocol treatment for patients assigned to Arms B or C.
- NOTE: Patients must also not breastfeed while on treatment and for 2 months after the last dose of treatment for patients assigned to Arm A and for 6 months after the last dose of treatment for patients assigned to Arms B or C
-
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
-
Leukocytes >= 3,000/mcL (must be obtained =< 14 days prior to protocol randomization)
-
Absolute neutrophil count (ANC) >= 1,500/mcL (must be obtained =< 14 days prior to protocol randomization)
-
Platelets >= 100,000/mcL (must be obtained =< 14 days prior to protocol randomization)
-
Hemoglobin (Hgb) > 9 g/dL (must be obtained =< 14 days prior to protocol randomization) (Note: Patient may be transfused to meet this criteria)
-
Total bilirubin =< 2.0 x institutional upper limit of normal (ULN) (=< 5.0 x institutional ULN if hepatic metastases present or =< 3 x ULN for patients with known Gilbert's disease) (must be obtained =< 14 days prior to protocol randomization)
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN (< 5.0 x institutional ULN if hepatic metastases present) (must be obtained =< 14 days prior to protocol randomization)
-
Alkaline phosphatase < 2.5 x institutional ULN (< 5.0 x institutional ULN if hepatic or bone metastases present) (must be obtained =< 14 days prior to protocol randomization)
-
Creatinine =< 1.5 x institutional ULN (must be obtained =< 14 days prior to protocol randomization)
-
Patients with uncontrolled or symptomatic hypercalcemia (ionized calcium > 1.5 mmol/L, calcium > 12 mg/dL or corrected serum calcium > ULN) must have their calcium levels corrected prior to randomization
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression. Patients must not have untreated brain metastases or leptomeningeal disease
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patients must not have uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Patients may have indwelling catheters (e.g., PleurX [registered trademark])
-
Patient must not have significant cardiovascular disease (such as New York Heart Association class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to randomization, or unstable arrhythmia or unstable angina at the time of randomization
-
Patient must not receive any other chemotherapy, immunotherapy, antitumor hormonal therapy (excluding contraceptives and replacement steroids), radiation therapy, or experimental medications while on protocol treatment. Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to randomization and patients must be recovered from the effects of radiation (there is no required minimum recovery period
-
Patient must not have had a surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to randomization, or anticipation of need for major surgical procedure while on protocol treatment
-
Patient must not have any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of the agents used in this protocol, may affect the interpretation of the results, or may render the patient at high risk from treatment complications
-
Patient must not have a history of abdominal fistula, gastrointestinal (GI) perforation, intra-abdominal abscess, or active GI bleeding within 6 months prior to randomization
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Phase II, Arm A (Cetuximab, Docetaxel, Cisplatin, Carboplatin)
Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study. |
Given IV
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Undergo blood sample collection
其他名称:
Undergo MRI
其他名称:
Undergo ECHO
其他名称:
Undergo CT scan
其他名称:
Undergo PET scan
其他名称:
Given IV
其他名称:
|
|
实验性的:Phase II, Arm B(Docetaxel, Cisplatin/Carboplatin, Bevacizumab)
Patients receive bevacizumab IV over 30-90 minutes on day 1 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-60 minutes on day 1 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study. |
Given IV
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Undergo blood sample collection
其他名称:
Undergo MRI
其他名称:
Undergo ECHO
其他名称:
Undergo CT scan
其他名称:
Undergo PET scan
其他名称:
|
|
实验性的:Phase II, Arm C (Bevacizumab, Atezolizumab)
Patients receive bevacizumab IV over 30-90 minutes on day 1 and atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study. |
Given IV
其他名称:
Undergo blood sample collection
其他名称:
Undergo MRI
其他名称:
Undergo ECHO
其他名称:
Undergo CT scan
其他名称:
Undergo PET scan
其他名称:
Given IV
其他名称:
|
|
实验性的:Phase III, Arm A (Cetuximab, Docetaxel, Cisplatin/Carboplatin)
Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 of each cycle, docetaxel IV over 1 hour on day 1 or days 1 and 8 of each cycle, and cisplatin IV or carboplatin IV on day 1 or days 1 and 8 of each cycle. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 or days 1 and 15 of each cycle of maintenance therapy. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, a PET scan, and/or MRI throughout the trial. Patients may undergo ECHO during screening. Patients undergo blood sample collection throughout the study. |
Given IV
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Undergo blood sample collection
其他名称:
Undergo MRI
其他名称:
Undergo ECHO
其他名称:
Undergo CT scan
其他名称:
Undergo PET scan
其他名称:
Given IV
其他名称:
|
|
实验性的:Phase III, Arm B (Chemotherapy, Bevacizumab, Atezolizumab)
Patients receive treatment as in Arm B or C above based on results of the Phase II trial. |
Given IV
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Undergo MRI
其他名称:
Undergo ECHO
其他名称:
Undergo CT scan
其他名称:
Undergo PET scan
其他名称:
Given IV
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
无进展生存期 (PFS)(第二阶段)
大体时间:从治疗开始到疾病进展或死亡的时间,从随机化开始评估长达 5 年
|
从治疗开始到疾病进展或死亡的时间,从随机化开始评估长达 5 年
|
|
|
Overall survival (OS) (Phase III)
大体时间:Time from treatment initiation until death from any cause, assessed up to 5 years from randomization
|
Will be compared using a stratified log rank test. |
Time from treatment initiation until death from any cause, assessed up to 5 years from randomization
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
不良事件发生率(第三阶段)
大体时间:治疗完成后最多 30 天
|
治疗完成后最多 30 天
|
|
|
OS in the subset of patients with high PD-L1 expression (Phase III)
大体时间:Up to 5 years from randomization
|
The interaction of PD-L1 by treatment will also be evaluated in a Cox proportional hazards model. |
Up to 5 years from randomization
|
|
Correlation between fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET) and computed tomography (CT) neck imaging biomarkers
大体时间:Up to 5 years from randomization
|
The two-sample t-test will be used to compare the difference of baseline 18F -FDG PET /CT imaging biomarkers (maximum standardized uptake value [SUVmax], metabolic tumor volume [MTV], total lesion glycolysis [TLG], tumor volume) between low and high expression of PD-L1. |
Up to 5 years from randomization
|
|
Prediction of treatment response
大体时间:Baseline up to 12 weeks
|
Determined by 18FDG-PET/CT and CT neck imaging biomarkers. To determine if 18FDG-PET/CT and CT neck imaging biomarkers at baseline will predict treatment response at nine to twelve weeks post-treatment, PFS, and OS Logistic regression model will be fit to assess the association of the 18F -FDG PET /CT imaging biomarkers (e.g., SUVmax, MTV, TLG, tumor heterogeneity, tumor volume) with binary treatment response at 9-12 weeks post treatment. Cox proportional hazards models will be fit to assess the association of 18F -FDG PET /CT imaging biomarkers with time-to-event outcomes (PFS or OS). |
Baseline up to 12 weeks
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Correlation between 18F-FDG PET and CT neck radiomics features and expression of PD-L1 expression
大体时间:Up to 5 years from randomization
|
The imaging textural features from radiomics analysis will be associated with the dichotomized PD-L1 expressions. First, proper transformation will be applied to the textural features as needed to address the distribution skewness. Second, Pearson or Spearman rank correlations will be calculated between all pairs of textural features to identify highly correlated features. Third, to address overfitting and high collinearity, machine learning techniques (e.g., LASSO or XGBoost) will be employed for feature selection during the association analysis with PD-L1 expressions. |
Up to 5 years from randomization
|
合作者和调查者
调查人员
- 首席研究员:Aarti Bhatia、ECOG-ACRIN Cancer Research Group
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 口腔疾病
- 口腔疾病
- 按部位分类的肿瘤
- 肿瘤
- 呼吸道疾病
- 组织学类型的肿瘤
- 头颈肿瘤
- 肿瘤、腺体和上皮
- 呼吸道肿瘤
- 耳鼻喉科疾病
- 咽部肿瘤
- 耳鼻咽喉肿瘤
- 鼻咽疾病
- 咽部疾病
- 癌,鳞状细胞
- 喉部疾病
- 鼻咽肿瘤
- 鼻咽癌
- 头颈部鳞状细胞癌
- 癌
- 喉肿瘤
- 口腔肿瘤
- 口咽肿瘤
- 下咽肿瘤
- 淋巴间质肺炎
- 氨基酸,肽和蛋白质
- 蛋白质
- 硫化合物
- 有机化学品
- 调查技术
- 临床实验室技术
- 诊断技术和程序
- 诊断
- 碳氢化合物
- 环磷脂
- 碳氢化合物,Alicyclic
- 碳氢化合物,循环
- 萜烯
- 抗体,单克隆,人源化
- 抗体,单克隆
- 抗体
- 免疫球蛋白
- 免疫蛋白
- 血蛋白
- 血清球蛋白
- 球蛋白
- 无机化学物质
- 氯化合物
- 氮化合物
- 协调配合物
- 税类
- 环虫
- 二萜
- 元素
- 金属
- 化学技术,分析
- 频谱分析
- 金属,重
- 免疫球蛋白同种型
- 硫化物
- 阴离子
- 离子
- 电解质
- 硫化氢
- 白金化合物
- 过渡元素
- 多西紫杉醇
- 贝伐单抗
- 西妥昔单抗
- 卡铂
- 免疫球蛋白G
- 顺铂
- 1,2-二氨基环己烷柠檬酸铂 II
- 标本处理
- 磁共振光谱
- 二硫化物
- 铂
- atezolizumab
- (225)AC-DOTA-C(RGDYK)
其他研究编号
- NCI-2021-10021
- U10CA180820 (美国 NIH 拨款/合同)
- NCI-2021-10021 (注册表标识符:CTRP (Clinical Trial Reporting Program))
- EA3202 (其他标识符:CTEP)
- EA3202 (其他标识符:ECOG-ACRIN Cancer Research Group)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.